EDAP TMS SA/ US2683111072 /
5/24/2024 9:44:44 PM | Chg. +0.09 | Volume | Bid- | Ask- | High | Low |
---|---|---|---|---|---|---|
6.12USD | +1.41% | 693 Turnover: 4,227.73 |
-Bid Size: - | -Ask Size: - | 6.13 | 6.07 |
GlobeNewswire
5/6
EDAP Announces Positive Final Results from the HIFI Study Comparing Outcomes of Focal One® HIFU Vers...
GlobeNewswire
4/23
EDAP Announces Final Results from HIFI Study Comparing Outcomes of Focal One® HIFU Versus Radical Pr...
GlobeNewswire
3/13
EDAP to Announce Fourth Quarter and Full-Year 2023 Financial Results on March 27, 2024
GlobeNewswire
3/6
EDAP to Present at the Oppenheimer 34th Annual Healthcare MedTech & Services Conference
GlobeNewswire
3/4
EDAP Announces FDA Breakthrough Device Designation for Focal One® in the Treatment of Deep Infiltrat...
GlobeNewswire
2/1
EDAP Announces Completion of Enrollment in Phase 3 Study Evaluating Focal One HIFU Therapy for the T...
GlobeNewswire
1/8
EDAP Announces Preliminary Fourth Quarter Record Focal One® System Sales and Placements
GlobeNewswire
1/2
EDAP Appoints Ken Mobeck, Global Chief Financial Officer, and Francois Dietsch, Global Chief Account...
GlobeNewswire
12/12/2023
EDAP Announces Positive Opinion for Reimbursement from the French National Authority for Health (HAS...
GlobeNewswire
11/30/2023
EDAP Receives 2023 Industry Category Award from the French National Institute for Intellectual Prope...
GlobeNewswire
10/26/2023
EDAP TMS SA to Announce Third Quarter 2023 Financial Results on November 9, 2023
GlobeNewswire
9/6/2023
EDAP to Present at Morgan Stanley Annual Global Healthcare Conference and the H.C. Wainwright Annual...
GlobeNewswire
3/21/2022
EDAP TMS SA to Announce Fourth Quarter 2021 Financial Results on Wednesday, March 30, 2022